Yeah, years ago the class looked bad. That's part of the reason...

Yeah, years ago the class looked bad. That's part of the reason Kazia ended up getting GDC-0084 for just 5 million dollars. We don't have to worry about safety concerns. " MEI-401 is a PI3 delta inhibitor and although it's specifically designed for an improved safety profile, this class of drugs has been hampered in the past by safety concerns."
Motley Fool article writer tries to make some generalization about the class, likely based on 5 year-old info.
Who can blame him/her, he/she was probably asked to research something and have an article out in an hour.

Trust your own research (and do it), don't pay attention to MF or Zacks or any of the myriad of other "investment research" bots. I get so annoyed when I read their crap because I know there are sheep who will believe what they say. Grrrrrr.